Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €137.36 EUR
Change Today -0.25 / -0.18%
Volume 1.6M
BAYN On Other Exchanges
As of 3:55 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - €146.45
52 Week Low
08/4/14 - €94.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BAYER AG-REG (BAYN)

bayer ag-reg (BAYN) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAYN) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as anticoagulants; medicines to treat hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension, high blood pressure, and infectious diseases; and contraceptives, as well as provides consumer health products, including over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; and contrast agent injection systems for diagnostic and therapeutic medical procedures in X-ray, computed tomography, and magnetic resonance imaging. The CropScience segment offers products in the areas of seeds and plant traits, and crop protection; and products for use in gardens and non-agricultural pest control, as well as green industry. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and specialty chemicals; and selected inorganic basic chemicals. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

119,478 Employees
Last Reported Date: 04/30/15
Founded in 1863

bayer ag-reg (BAYN) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €520.0K
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €2.0M
Labor Director and Member of Management Board
Total Annual Compensation: €1.6M
Member of Management Board, Chief Medical Off...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

bayer ag-reg (BAYN) Key Developments

Bayer Seeks Acquisitions

Bayer AG (DB:BAYN) Chief Executive Officer Marijn Dekkers is listing a plastics business on the stock market as he focuses on more lucrative life-sciences operations and also has expressed interest in acquisitions in veterinary medicines.

Sinocare Interested In Diabetes Devices Business from Bayer

Sinocare Inc. (SZSE:300298) intends to submit bid to acquire diabetes device business from Bayer AG (DB:BAYN), reported Bloomberg, citing people familiar with the matter. According to the reports, Sinocare made an offer of about $1 billion with GoldStone Investment Ltd., the direct-investment unit of CITIC Securities Company Ltd. Sinocare has reached out to Chinese banks to seek financing for a potential deal. Sinocare is competing with Panasonic Healthcare Co, backed by KKR & Co., which has been holding talks to buy the Bayer unit from February 2015, the sources said.

Bayer AG Announces Consolidated Earnings Results for the First Quarter Ended March 2015; Raises Financial Guidance for the Full Year of 2015

Bayer announced consolidated earnings results for the first quarter ended March 2015. The company announced that its net profits were down in the first three months. The company said that its after-tax profits declined by 8.4% to EUR 1.303 billion in the period from January to March. This was due to special charges related to the integration of acquired businesses, the consolidation of production sites and additional efficiency improvement measures. Underlying or operating profit before special items was up 9.6% at EUR 3.9 billion, and sales jumped by 14.8% to EUR 12.117 billion. Reported EBIT fell 5% to EUR 2 billion. Earnings were diminished by special charges of EUR 244 million, mainly due to expenses for the integration of acquired businesses, consolidation of production sites and additional efficiency improvement measures. Including the contributions from the acquired businesses, adjusted EBITDA for the group posted an increase of 10% to EUR 3 billion. This good Core earnings per share amounted to EUR 2.10, an increase of 8% over the prior year. As a result of the improvement in EBITDA, gross cash flow inched up 1% in the quarter. Net cash flow more than quadrupled to over EUR 720 million as less funds were tied up in working capital versus the prior year. With capital expenditures of almost EUR 350 million, the free operating cash flow came in at roughly EUR 380 million. Net financial debt at the end of the quarter stood at EUR 21.3 billion, an increase of EUR 1.7 billion from year-end 2014, mainly due to currency. Nevertheless the company has raised its full-year forecasts due to the positive effects of the weak euro. The company now expect group sales between EUR 48 billion and EUR 49 billion versus previously EUR 46 billion. This corresponds to a currency and portfolio-adjusted increase in the low single-digit percentage. For adjusted EBITDA, the company now anticipate an increase in the high-teens percentage versus previously in the low- to mid-teens percentage. And this includes a positive currency impact of 8%. Core earnings per share, the company now expect to increase in the high-teens percentage versus previously in the low-teens percentage, including a positive currency effect of 7%. For the group as a whole, The company expects to deliver significant sales and earnings growth in 2015. Overall, The company expects that for the full year, the net debt will go below EUR 20 billion again.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYN:GR €137.36 EUR -0.25

BAYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $301.35 USD +0.13
Bristol-Myers Squibb Co $68.30 USD -0.59
GlaxoSmithKline PLC 1,465 GBp +14.00
Novo Nordisk A/S kr388.00 DKK +3.50
Sanofi €92.30 EUR -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation BAYN Industry Range
Price/Earnings 35.7x
Price/Sales 2.7x
Price/Book 5.4x
Price/Cash Flow 35.7x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at